

**Mr Haitham Hamoda MD FRCOG**  
**Consultant Gynaecologist,**  
**Subspecialist in Reproductive Medicine and Surgery**  
**Clinical Lead Menopause Service**  
**King's College Hospital**  
**Trustee and Past Chair British Menopause Society**

Mr Haitham Hamoda is a Consultant Gynaecologist and Subspecialist in Reproductive Medicine and Surgery and the Lead for the Menopause Service at King's College Hospital. He is Trustee and past Chair of the British Menopause Society.

Mr Hamoda has published widely in his specialised field and is actively involved in ongoing research projects both locally and nationally.

He is first author of The British Menopause Society & Women's Health Concern 2020 recommendations on hormone replacement therapy in menopausal women and author of the British Menopause Society guideline on the management of women with premature ovarian insufficiency 2017.

Mr Hamoda is a Fellow of the Royal College of Obstetricians and Gynaecologists and was awarded a degree of Doctor of Medicine (MD) from the University of Aberdeen. He obtained his accreditation as a subspecialist in reproductive medicine at Guy's and St Thomas' Hospital.

### **Current Position:**

Consultant Gynaecologist, Subspecialist in Reproductive Medicine and Surgery at King's College Hospital, London.

Lead for the Menopause Services at King's College Hospital.

Trustee and Past Chair British Menopause Society

### **Special interest areas:**

Menopause and premature ovarian Insufficiency

Infertility and assisted reproduction

Minimal access surgery (laparoscopic and hysteroscopic)

Fibroids and endometriosis

Gynaecological ultrasound scanning

Gynaecological endocrinology including PCOS, PMS, PMDD

**Qualifications:**

**March 2007**

**MD University of Aberdeen**

**November 2000**

**MRCOG Royal College of Obstetricians & Gynaecologists**

**Recent appointments held:**

**January 2011 to present**

**Consultant Gynaecologist, (Subspecialist in Reproductive Medicine and Surgery) King's College Hospital.**

**February 2009 to January 2011**

**Subspecialty Accreditation in Reproductive Medicine Guy's and St Thomas' Hospital.**

## **Publications:**

### **Books:**

- **Management of the Menopause 6<sup>th</sup> Edition.**

### **Book Chapters:**

- **Assisted reproduction: role in the management of infertility.**

Vigneswaran K, Hamoda H. In, Reproductive Medicine for the MRCOG 2021.

- **Menopause and Hormone Replacement Therapy.**

Vigneswaran K, Hamoda H. In, The EBCOG Postgraduate Textbook of Obstetrics & Gynaecology 2021.

- **Estrogens and progestogens used in HRT, including modes of administration.**

Vigneswaran K, Hamoda H.. In, managing the Menopause 2020.

- **The patient with previous uterine artery embolisation.**

Vigneswaran K, Hamoda H. In, Assisted Reproduction Techniques: Challenges and Management Options: 2<sup>nd</sup> Edition 2021.

- **The patient with uterine fibroids.**

Vigneswaran K, Hamoda H. In, Assisted Reproduction Techniques: Challenges and Management Options: 2<sup>nd</sup> Edition 2021.

- **Pre-IVF care: selection of cases, screening, preparation, investigations.**

H Hamoda in ASSISTED REPRODUCTIVE TECHNOLOGY 2015.

- **Assisted Reproduction: Preparation and work up of couples.**

H Hamoda in 'Infertility for the MRCOG and beyond, 3rd Edition, 2014.

- **Premature Ovarian Insufficiency and Its fertility implications.**

M Savvas and H Hamoda. Frontiers in Gynecological Endocrinology, ISGE Series, DOI 10.1007/978-3-319-03494-2\_2; 2014.

- **Treatment with Donor Eggs.**

M Savvas, H Hamoda, and M Mittal Frontiers in Gynecological Endocrinology, ISGE Series, DOI 10.1007/978-3-319-03494-2\_2; 2014.

- **Aneuploidy screening and repeated IVF failure.**

H Hamoda & Y Khalaf in Sharif & Coomarasamy - Assisted Reproduction Techniques: Challenges & Management Options. 2012.

- **The patient with previous uterine artery embolisation.**  
H Hamoda & Y Khalaf in Sharif & Coomarasamy - Assisted Reproduction Techniques: Challenges & Management Options. 2012.
- **The patient with uterine fibroids.**  
H Hamoda & Y Khalaf in Sharif & Coomarasamy - Assisted Reproduction Techniques: Challenges & Management Options. 2012.
- **Assisted Reproduction.**  
H Hamoda in 'Infertility for the MRCOG and beyond (2<sup>nd</sup> Edition)' 2006.
- **Epidemiology of infertility.** H Hamoda STRAT OG: RCOG Distance Learning Programme (Module 8), 2005.

#### **Selected published papers:**

- **Accessible high quality menopause education for healthcare professionals.**  
  
Currie H., Hamoda H., Ellis K., Verstringhe N., Haveron Jones S., Halstead B., Riley H.  
  
Post Reproductive Health. 30(2) (pp 71-72), 2024. Date of Publication: June 2024.  
  
[Editorial] Publisher: SAGE Publications Ltd
- **Management of unscheduled bleeding on HRT: A joint guideline on behalf of the British Menopause Society, Royal College Obstetricians and Gynaecologists, British Gynaecological Cancer Society, British Society for Gynaecological Endoscopy, Faculty of Sexual and Reproductive Health, Royal College of General Practitioners and Getting it Right First Time.**  
  
Manley K., Hillard T., Clark J., Kumar G., Morrison J., Hamoda H., Barber K., Holloway D., Middleton B., Oyston M., Pickering M., Sassarini J., Williams N.  
  
Post Reproductive Health. 30(2) (pp 95-116), 2024. Date of Publication: June 2024.
- **Premature ovarian insufficiency, early menopause, and induced menopause.**

Sharma A and Hamoda H Best Practice and Research Clinical Endocrinology and Metabolism on The Menopause - Diagnostic and Therapeutic Strategies 2024.

- **Menopause care for women: Supporting the NHS to support women.**

Briggs P., Hamoda H., Rymer J., Morris E., Moger S. Post Reproductive Health. 29(1) (pp 4-5), 2023. Date of Publication: March 2023. [Editorial] Publisher: SAGE Publications Ltd

- **An evaluation of menopause service delivery during the COVID-19 pandemic.**

Pedder H., Robinson L., Abernethy K., Hamoda H., Marsden J. Post Reproductive Health. 29(2) (pp 85-93), 2023. Date of Publication: June 2023.

- **EMAS position statement: Vitamin D and menopausal health.**

Anagnostis P., Livadas S., Goulis D.G., Bretz S., Ceausu I., Durmusoglu F., Erkkola R., Fistonc I., Gambacciani M., Geukes M., Hamoda H., Hartley C., Hirschberg A.L., Meczekalski B., Mendoza N., Mueck A., Smetnik A., Stute P., van Trotsenburg M., Rees M., Lambrinoudaki I. Maturitas. 169 (pp 2-9), 2023. Date of Publication: March 2023.

- **The pathophysiology and management of menopausal symptoms.**

Vigneswaran K., Hamoda H. Obstetrics, Gynaecology and Reproductive Medicine. 33(5) (pp 135-140), 2023. Date of Publication: May 2023.

- **Editorial: Looking at HRT in perspective.**

Hamoda H. & Moger S. The BMJ. <https://doi.org/10.1136/bmj.o1425>. 2022.

- **Menopause practice standards.**

Hamoda H., Moger S., Morris E., Baldeweg S.E., Kasliwal A., Gabbay F. Clinical Endocrinology: 2022.

- **Optimizing the menopause transition: Joint position statement by the British Menopause Society, Royal College of Obstetricians and Gynaecologists and Society for Endocrinology on best practice recommendations for the care of women experiencing the menopause.**

Hamoda H., Mukherjee A., Morris E., Baldeweg S.E., Jayasena C.N., Briggs P., Moger S. Clinical Endocrinology. Date of Publication: 2022.

- **Menopause practice standards.**

Hamoda H., Moger S., Morris E., Baldeweg S., Kasliwal A., Gabbay F., Wright H.

Post Reproductive Health. 28(3) (pp 127-132), 2022. Date of Publication: September 2022.

- **Impact of micronised progesterone and medroxyprogesterone acetate in combination with transdermal oestradiol on cardiovascular markers in women diagnosed with premature ovarian insufficiency or an early menopause: a randomised pilot trial.**  
Mittal M., McEniery C., Supramaniam P.R., Cardozo L., Savvas M., Panay N., Hamoda H. Maturitas. 161 (pp 18-26), 2022. Date of Publication: July 2022.
- **Editorial: Optimising the menopause transition: Joint position statement by the British Menopause Society, Royal College of Obstetricians and Gynaecologists and Society for Endocrinology on best practice recommendations for the care of women experiencing the menopause.**  
Hamoda H., Mukherjee A., Morris E., Baldeweg S.E., Jayasena C.N., Briggs P., Moger S. Post Reproductive Health. 28(3) (pp 121-122), 2022. Date of Publication: September 2022.
- **Androgens in postmenopausal women.**  
Vigneswaran K., Hamoda H. Obstetrician and Gynaecologist. 24(4) (pp 228-241), 2022. Date of Publication: October 2022.
- **The effect of micronized progesterone and medroxyprogesterone acetate in combination with transdermal estradiol on hemostatic biomarkers in postmenopausal women diagnosed with POI and early menopause: A randomized trial.**  
Mittal M., Chitongo P., Supramaniam P.R., Cardozo L., Savvas M., Panay N., Arya R., Hamoda H. Menopause. 29(5) (pp 580-589), 2022. Date of Publication: 07 May 2022.
- **Transfer of thawed frozen embryo versus fresh embryo to improve the healthy baby rate in women undergoing IVF: The E-Freeze RCT.**  
Maheshwari A., Bari V., Bell J.L., Bhattacharya S., Bhide P., Bowler U., Brison D., Child T., Chong H.Y., Cheong Y., Cole C., Coomarasamy A., Cutting R., Goodgame F., Hardy P., Hamoda H., Juszczak E., Khalaf Y., King A., Kurinczuk J.J., Lavery S., Lewis-Jones C., Linsell L., Macklon N., Mathur R., Murray D., Pundir J., Raine-Fenning N., Rajkohwa M., Robinson L., Scotland G., Stanbury K., Troup S. Health Technology Assessment. 26(25) (no pagination), 2022. Date of Publication: 2022.
- **Developing the Women's health strategy: The British Menopause Society's recommendations to the department of health and social care's call for evidence.**  
Hamoda H., Moger S. Post Reproductive Health. 28(1) (pp 13-18), 2022. Date of Publication: March 2022.
- **Hormone replacement therapy - Current recommendations.**

Vigneswaran K., Hamoda H.

Best Practice and Research: Clinical Obstetrics and Gynaecology. 81 (pp 8-21), 2022.

Date of Publication: May 2022.

- **Menopause, wellbeing and health: A care pathway from the European Menopause and Andropause Society.**

Lambrinoudaki I., Armeni E., Goulis D., Bretz S., Ceausu I., Durmusoglu F., Erkkola R., Fistonc I., Gambacciani M., Geukes M., Hamoda H., Hartley C., Hirschberg A.L., Meczekalski B., Mendoza N., Mueck A., Smetnik A., Stute P., van Trotsenburg M., Rees M.

Maturitas. 163 (pp 1-14), 2022. Date of Publication: September 2022.

- **Elective freezing of embryos versus fresh embryo transfer in IVF: A multicentre randomized controlled trial in the UK (E-Freeze).**

Maheshwari A., Bell J.L., Bhide P., Brison D., Child T., Chong H.Y., Cheong Y., Cole C., Coomarasamy A., Cutting R., Hardy P., Hamoda H., Juszczak E., Khalaf Y., Kurinczuk J.J., Lavery S., Linsell L., MacKlon N., Mathur R., Pundir J., Raine-Fenning N., Rajkohwa M., Scotland G., Stanbury K., Troup S., Bhattacharya S.

Human Reproduction. 37(3) (pp 476-487), 2022. Date of Publication: 01 Mar 2022.

- **The essential menopause curriculum for healthcare professionals: A European Menopause and Andropause Society (EMAS) position statement.**

Rees M., Abernethy K., Bachmann G., Bretz S., Ceausu I., Durmusoglu F., Erkkola R., Fistonc I., Gambacciani M., Geukes M., Goulis D.G., Griffiths A., Hamoda H., Hardy C., Hartley C., Hirschberg A.L., Kydd A., Marshall S., Meczekalski B., Mendoza N., Mueck A., Persand E., Riach K., Smetnik A., Stute P., van Trotsenburg M., Yuksel N., Weiss R., Lambrinoudaki I.

Maturitas. 158 (pp 70-77), 2022. Date of Publication: April 2022.

**Editorial: Women's Health Strategy: Time to have women's voices at the top of the agenda.**

Hamoda H., Moger S.

Post Reproductive Health. 28(1) (pp 5-7), 2022. Date of Publication: March 2022.

[Editorial]

SAGE Publications Ltd

- **British Menopause Society tools for clinicians: Progestogens and endometrial protection.**

Hamoda H.

Post Reproductive Health. 28(1) (pp 40-46), 2022. Date of Publication: March 2022.



- **Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: A consensus document from European cardiologists, gynaecologists, and endocrinologists.**  
 Maas A.H.E.M., Rosano G., Cifkova R., Chieffo A., Van Dijken D., Hamoda H., Kunadian V., Laan E., Lambrinouadaki I., MacLaran K., Panay N., Stevenson J.C., Van Trotsenburg M., Collins P.  
 European Heart Journal. 42(10) (pp 967-984), 2021. Date of Publication: 07 Mar 2021.
- **The silent epidemic of urogenital atrophy.**  
 Briggs P., Delanerolle G., Burton R., Shi J.Q., Hamoda H., Hapangama D.K.  
 British Journal of General Practice. 71(713) (pp 538-539), 2021. Date of Publication: December 2021.
- **Cardiometabolic health in premature ovarian insufficiency.**  
 Stevenson J.C., Collins P., Hamoda H., Lambrinouadaki I., Maas A.H.E.M., Maclaran K., Panay N.  
 Climacteric. 24(5) (pp 474-480), 2021. Date of Publication: 2021.
- **A cross-sectional national questionnaire survey assessing the views of members of the British Menopause Society on the management of patients with unscheduled bleeding on hormone replacement therapy.**  
 Abdullahi Idle S., Panay N., Hamoda H.  
 Post Reproductive Health. 27(3) (pp 159-165), 2021. Date of Publication: September 2021.
- **BMS, RCOG, RCGP, FSRH, FOM and FPH Position Statement in response to the BMA report 'Challenging the culture on menopause for doctors' - August 2020.**  
 Hamoda H., Morris E., Marshall M., Kasliwal A., Bono A.D., Rae M.  
 Post Reproductive Health. 27(2) (pp 123-125), 2021. Date of Publication: June 2021.
- **Vision for menopause care in the UK.**  
 Currie H., Abernethy K., Hamoda H.  
 Post Reproductive Health. 27(1) (pp 10-18), 2021. Date of Publication: March 2021.
- **Editorial: Impact of the COVID-19 pandemic on the delivery of menopause education and training.**  
 Hamoda H., Moger S.  
 Post Reproductive Health. 27(1) (pp 3-4), 2021. Date of Publication: March 2021.
- **BMS, IMS, EMAS, RCOG and AMS joint statement on menopausal hormone therapy and breast cancer risk in response to EMA Pharmacovigilance Risk Assessment Committee recommendations in May 2020.**

- Hamoda H., Davis S.R., Cano A., Morris E., Davison S., Panay N., Lumsden M.A., Hillard T., Simoncini T.  
Post Reproductive Health. 27(1) (pp 49-55), 2021. Date of Publication: March 2021.
- **A direct comparison of women's perceptions and acceptability of micronised progesterone and medroxyprogesterone acetate in combination with transdermal oestradiol in the management of young postmenopausal women, under 45 years of age.**  
Mittal M., Panay N., Supramaniam P.R., Savvas M., Cardozo L., Hamoda H.  
Post Reproductive Health. 26(4) (pp 210-219), 2020. Date of Publication: December 2020.
  - **The British Menopause Society & Women's Health Concern 2020 recommendations on hormone replacement therapy in menopausal women.**  
Hamoda H., Panay N., Pedder H., Arya R., Savvas M., on behalf of the Medical Advisory Council of the British Menopause Society  
Post Reproductive Health. 26(4) (pp 181-209), 2020. Date of Publication: December 2020.
  - **Editorial: Availability of menopausal hormone therapy products worldwide.**  
Hamoda H.  
Maturitas. 141 (pp 87-88), 2020. Date of Publication: November 2020.
  - **A Randomized trial of endometrial scratching before in vitro fertilization.**  
Lensen S., Osavlyuk D., Armstrong S., Stadelmann C., Hennes A., Napier E., Wilkinson J., Sadler L., Gupta D., Strandell A., Bergh C., Vigneswaran K., Teh W.T., Hamoda H., Webber L., Wakeman S.A., Searle L., Bhide P., McDowell S., Peeraer K., Khalaf Y., Farquhar C. New England Journal of Medicine. 380 (4) (pp 325-334), 2019. Date of Publication: 24 Jan 2019. [Article] AN: 626070759 Publisher Massachusetts Medical Society.
  - **Joint position statement by the British Menopause Society, Royal College of Obstetricians and Gynaecologists and Society for Endocrinology on best practice recommendations for the care of women experiencing the menopause.**  
Hamoda H., Mukherjee A., Morris E., Baldeweg S.E., Jayasena C.N., Briggs P., Moger S.  
Post Reproductive Health. 28(3) (pp 123-125), 2022. Date of Publication: September 2022.  
[Article]
  - **Experience of hormone replacement therapy in postmenopausal women living with HIV.**  
Howells P., Modarres M., Samuel M., Taylor C., Hamoda H.

Post Reproductive Health. (no pagination), 2019. Date of Publication: 2019.  
AN: 626912965 Publisher SAGE Publications Ltd (E-mail: info@sagepub.co.uk)

- **Hormone replacement therapy: Changes in prescribing practice.**  
Davies M., Hamoda H.  
BMJ (Online). 364 (no pagination), 2019. Article Number: l633. Date of Publication: 2019.  
[Letter] AN: 626315338 Publisher BMJ Publishing Group (E-mail: [subscriptions@bmjgroup.com](mailto:subscriptions@bmjgroup.com))
- **Outcomes of endometrial assessment in women with unscheduled bleeding on hormone replacement therapy.**  
Abdullahi Idle S., Hamoda H.  
Post Reproductive Health. (no pagination), 2019. Date of Publication: 2019.  
[Article] AN: 626513900 Publisher SAGE Publications Ltd (E-mail: info@sagepub.co.uk)
- **Outpatient management of severe ovarian hyperstimulation syndrome: a systematic review and a review of existing guidelines.**  
Gebriel A., Hamoda H., Mathur R.  
Human Fertility. 21 (2) (pp 98-105), 2018. Date of Publication: 03 Apr 2018.  
[Review] AN: 621800618 Publisher Taylor and Francis Ltd (E-mail: [healthcare.enquiries@informa.com](mailto:healthcare.enquiries@informa.com))
- **The British Menopause Society and Women's Health Concern recommendations on the management of women with premature ovarian insufficiency.**  
H Hamoda on behalf of the British Menopause Society and Women's Health Concern.  
Post Reprod Health. 2017 Mar;23(1):22-35. doi: 10.1177/2053369117699358. PubMed PMID: 28381102.
- **The British Menopause Society & Women's Health Concern 2016 recommendations on hormone replacement therapy in menopausal women.**  
H Hamoda, N Panay, R Arya, and M Savvas on behalf of The British Menopause Society and Women's Health Concern. Post Reproductive Health 2016, Vol. 22(4) 165–183.
- **Outpatient management of severe ovarian hyperstimulation syndrome: a systematic review and a review of existing guidelines.** Gebriel A, Hamoda H, Mathur R. Hum Fertil (Camb). 2017 May 29;1-8. doi: 10.1080/14647273.2017.1331048. [Epub ahead of print] PubMed PMID: 28554223.
- **Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis.**  
Achilli C, Pundir J, Ramanathan P, Sabatini L, Hamoda H, Panay N.  
Fertil Steril. 2017 Feb;107(2):475-482.e15. doi: 10.1016/j.fertnstert.2016.10.028. Epub 2016 Dec 1. PubMed PMID: 27916205.
- **The Management of Ovarian Hyperstimulation Syndrome** Green-top Guideline No. 5 for the Royal College of Obstetricians and Gynaecologists. February 2016.  
RS Mathur, AJ Drakeley, NJ Raine-Fenning, Nottingham, IO Evbuomwan, and H Hamoda.
- **Long-term benefits and risks of HRT (Section 11): Venous thromboembolism.**  
Hamoda H. Post Reproductive Health. 22 (2); (77-79), 2016.

- **Intermediate and long-term outcomes following uterine artery fibroid embolization.**  
Hamoda H, Pepas L, Tasker F, Reidy J, Khalaf Y.  
Eur J Obstet Gynecol Reprod Biol. 2015 Aug;191:33-8. doi:  
10.1016/j.ejogrb.2015.05.016.
- **The 2013 British Menopause Society & Women's health concern recommendations on hormone replacement therapy.**  
N Panay, H Hamoda, R Arya, M Savvas.  
Menopause International. 2013; 19 (2) (pp 59-68).
- **A randomized controlled trial comparing the effects of micronized progesterone to medroxyprogesterone acetate on cardiovascular health, lipid metabolism and the coagulation cascade in women with premature ovarian insufficiency: Study protocol and review of the literature.**  
M Mittal, M Savvas, R Arya, E McEniery, N Narvekar, L Cardozo, N Panay, H Hamoda.  
Menopause International. 2013; 19 (3) (pp 127-132).
- **A cross-sectional national survey assessing the clinical attitudes to the management of premature ovarian insufficiency.**  
M Mittal, M Savvas, N Narvekar, N Panay, H Hamoda.  
Menopause International. 2013; 19 (3) (pp 108).
- **New guidelines for hormone-replacement therapy: An update on risks and benefits for clinical practice.**  
H Hamoda, M Savvas, N Panay.  
Clinical Practice. 2013; 10 (6): 675-678.
- **Fertility desires, choice of hormone replacement and the effect of length of time since menopause on bone density in women with premature ovarian insufficiency: a review of 223 consecutive new referrals to a tertiary centre.**  
M Mittal, M Kreatsa, N Narvekar, M Savvas, H Hamoda.  
Post reproductive health. 2014; 20(3): 104-11.
- **What should we be advising women about hormone replacement therapy?**  
H Hamoda, M Savvas.  
InnovAiT: Education and inspiration for general practice. 2014; 7, 5: 295-300.
- **Sperm donor recruitment, attitudes and provider practices-5 years after the removal of donor anonymity.**  
U Shukla, B Deval, M Jansa Perez, H Hamoda, M Savvas, N Narvekar.  
Human Reproduction. 2013; 28 (3); 676-682.
- **Effect of heparin on the outcome of IVF treatment: A systematic review and meta-analysis.**  
S Seshadri, SK Sunkara, Y Khalaf, T El-Toukhy, H Hamoda.  
Reproductive BioMedicine Online. 2012; 25 (6); 572-584.

- **Scheduling PGD cycles to a two-day oocyte collection week: outcomes compared to standard IVF cycles in a five-day oocyte collection week programme.** H Hamoda, L Pepas, C Freed, J Grace, Y Khalaf, P Braude, T El-Toukhy. *Human Fertility* 2011; 14(4):254-60.
- **Hyperprolactinaemia and female reproductive function: What does the evidence say?** *The Obstetrician and Gynaecologist*. 2012; H Hamoda, Y Khalaf, P Carroll. 2012; 14: 81–86.
- **Menstrual and reproductive outcomes following uterine artery fibroid embolisation: A literature review.** H Hamoda and Y Khalaf. *Current Reviews for Women’s Health*. 2010; 6(4): 273-275.
- **Oogenesis and cell death in human prenatal ovaries: what are the criteria for oocyte selection?** GM Hartshorne, S Lyrakou, H Hamoda, E Oloto, and F Ghafari. *Molecular Human Reproduction*. 2009; 15(5): 805-820.
- **Medical and Surgical options for induced Abortion in First Trimester.** H Hamoda and A Templeton. *Best Practice & Research Clinical Obstetrics & Gynaecology*. April 2010.
- **A randomised trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion at 13-20 weeks gestation.** H Hamoda, PW Ashok, GMM Flett, A Templeton. *Human Reproduction*. 2005; 20(8): 2348-2354.
- **A randomised controlled trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion up to 13 weeks gestation.** H Hamoda, PW Ashok, GMM Flett, A Templeton. *BJOG*. 2005; 112(8): 1102-1108.
- **Home self-administration of misoprostol for medical abortion up to 56 days gestation.** H Hamoda, PW Ashok, GMM Flett, A Templeton. *The Journal of Family Planning and Reproductive Health Care*. 2005; 31(3):189-192.
- **Surgical abortion using manual vacuum aspiration under local anaesthesia: a pilot study of feasibility and women’s acceptability.** H Hamoda, GMM Flett, PW Ashok, A Templeton. *The Journal of Family Planning and Reproductive Health Care* 2005; 31(3):185-188.
- **The acceptability of home medical abortion to women in UK settings.** H Hamoda, H OD Critchley, K Paterson, K Guthrie, M Rodger, G C Penney. *BJOG*. 2005; 112(6):781-785.
- **Uptake and efficacy of medical abortion at 9-13 weeks gestation: A review of 1076 consecutive cases.** H Hamoda, PW Ashok, GMM Flett, A Templeton. *Contraception*. 2005; 71(5):327-332.

- **Medical termination of pregnancy in the early first trimester.** H Hamoda, GMM Flett. *The Journal of Family Planning and Reproductive Health Care.* 2005; 31(1):10-14.
- **A randomised controlled trial of levonorgestrel versus 10 mg mifepristone for postcoital emergency contraception up to 120 hours.** H Hamoda, PW Ashok, C Stalder, GMM Flett, E Kennedy, A Templeton. *Obstetrics & Gynecology.* 2004; 104: 1307-1313.
- Analgesia requirements and predictors of analgesia use for women undergoing medical abortion up to 22 weeks gestation. H Hamoda, PW Ashok, GMM Flett and A Templeton. *BJOG.* 2004; 111, 996-1000.
- **A randomised controlled trial of sublingual and vaginal administration of misoprostol for cervical priming prior to first-trimester surgical abortion.** H Hamoda, PW Ashok, GMM Flett, A Templeton. *American Journal of Obstetrics & Gynecology.* 2004; 190(1):55-9.
- **A pilot study of mifepristone in combination with sublingual or vaginal misoprostol for medical termination of pregnancy up to 63 days gestation.** H Hamoda, PW Ashok, J Dow, GMM Flett, A Templeton. *Contraception.* 2003; 68(5):335-8.
- **Medical abortion at 64-91 days gestation: A review of 483 consecutive cases.** H Hamoda, PW Ashok, GMM Flett, A Templeton. *American Journal of Obstetrics and Gynecology.* 2003; 188(5):1315-9.
- **Pelvic infections.** H Hamoda, C Bignell. *Current Obstetrics and Gynaecology.* 2002; 12, 185-190.
- **Psychological sequelae of medical and surgical abortion at 10–13 weeks gestation.** PW Ashok, H Hamoda, G MM Flett, A Kidd, A Fitzmaurice, A Templeton. *Acta Obstetrica et Gynecologica Scandinavica.* 2005; 84(8):761-766.
- **Patient preference in a randomised study comparing medical and surgical abortion at 10–13 weeks gestation.** PW Ashok, H Hamoda, G MM Flett, A Kidd, A Fitzmaurice, A Templeton. *Contraception.* 2005; 71(2):143-148.
- **Mifepristone versus the Yuzpe regimen (PC4) for emergency contraception.** PW Ashok, H Hamoda, GMM Flett, A Templeton. *International Journal of Gynecology & Obstetrics.* 2004; 87(2):188-93.
- **Randomised controlled study comparing oral and vaginal misoprostol for cervical priming prior to surgical termination of pregnancy.** PW Ashok, H Hamoda, F Nathani, GMM Flett, A Templeton. *BJOG.* 2003; 110(12):1057-6

**Commentaries and case reports:**

- **Fatal pulmonary embolus after uterine artery fibroid embolisation.** H Hamoda, P Tait and DK Edmonds. Cardiovascular and interventional radiology 2009;32(5):1080-2.
- **Commentary: Similar emergency contraception failure rates for 24-hour and 12-hour double-dose regimens of levonorgestrel:** H Hamoda, A Templeton. Evidence-Based Obstetrics & Gynecology. 2005; 7(4): 191-192.
- **Commentary: Sublingual misoprostol was as efficacious as vaginal for early termination of pregnancy but had more side effects.** H Hamoda, PW Ashok, A Templeton. Evidence-based Obstetrics & Gynecology. 2004; 6(2), 74-75.
- **Conservative treatment of an incarcerated gravid uterus.** H Hamoda, PF Chamberlain, NR Moore, IZ Mackenzie. BJOG. 2002; 109, 1074-1075.
- **Clostridium welchii infection following amniocentesis: A case report and review of the literature.** H Hamoda, PF Chamberlain. Prenatal Diagnosis. 2002; 22, 783-785.

